Ku EJ, et al. - In patients with inadequately controlled type 2 diabetes (T2D), researchers, for the first time, directly compared the safety and efficacy between empagliflozin and dapagliflozin, as part of a quadruple oral antidiabetic agent (OADs) regimen. Participants in the study included T2D patients with glycated hemoglobin (HbA_1c) ranging 7.5%–12.0% with metformin, glimepiride, and dipeptidyl peptidase-4 inhibitors. Patients were divided into either empagliflozin (25 mg/day) or dapagliflozin (10 mg/day) treatment groups. A total of 350 patients were enrolled: empagliflozin (n=176) and dapagliflozin (n=174). Both groups showed significant decreases in HbA_1c and fasting plasma glucose after 52 weeks, but the decrease in the empagliflozin group was greater. Both groups demonstrated significantly reduced blood pressure and body weight and high-density lipoprotein cholesterol levels were increased in the empagliflozin group. Overall, in T2D patients treated with three other OADs, SGLT2 inhibitors may be used effectively as a fourth OAD. In particular, empagliflozin was more effective than dapagliflozin in reducing HbA_1c and improving other cardiometabolic parameters. Both groups, however, demonstrated similar safety profiles.